22 December 2021

nanosynth group plc

("nanosynth", the "Company" or the "Group")

Board change

nanosynth group plc, the AIM quoted company is pleased to announce that Dr Gareth Cave, currently a Non-executive Director of the Company, has today been appointed as an Executive Director and as the Group's Chief Scientific Officer. Dr Cave's intended change of role, which at that time was subject to contract, was announced on 1 September 2021.

Dr Cave is a university chemistry lecturer and has spent his academic career researching many applications of nanotechnology, from drug delivery systems to plant food.  Beyond academia, as an active consultant, he shares his knowledge and know-how across a plethora of industries including pharmaceutical, healthcare, materials, agricultural, food and drink industries.  In 2015 he formed Pharm 2 Farm Ltd, a wholly owned subsidiary of nanosynth group plc, as a university spinout, to help realise the full commercial potential of this nanotechnology research.

He has B.Sc., M.Sc. and Ph.D. chemistry degrees from the University of Warwick, is an active member of the Royal Society of Chemistry and has worked as an academic in UK, USA and Australian universities over the course of his career.

Mark Duffin, CEO commented: "I am delighted to formalise the agreement for Gareth to become part of the Executive team as Chief Scientific Officer. His skills and experience are ideally suited to guiding us through this exciting and innovative time in the Group's development."

The information contained within this announcement is deemed by the Company to constitute inside information as stipulated under the Market Abuse Regulations (EU) No. 596/2014 ('MAR') which has been incorporated into UK law by the European Union (Withdrawal) Act 2018.  Upon the publication of this announcement via Regulatory Information Service ('RIS'), this inside is now considered to be in the public domain.

ENQUIRIES :